164 related articles for article (PubMed ID: 15312147)
1. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaco-proteomic analysis: application of proteomic analysis to the discovery and development of new drugs].
Chapal N; Laplanche M; Ribes G; Pau B; Garin J; Petit P
J Soc Biol; 2002; 196(4):317-22. PubMed ID: 12645303
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view?
Kraljevic S; Sedic M; Scott M; Gehrig P; Schlapbach R; Pavelic K
Cancer Treat Rev; 2006 Dec; 32(8):619-29. PubMed ID: 17069979
[TBL] [Abstract][Full Text] [Related]
5. Oncoproteomics.
Joshi S; Tiwari AK; Mondal B; Sharma A
Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
[TBL] [Abstract][Full Text] [Related]
6. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
Smith L; Lind MJ; Welham KJ; Cawkwell L;
Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
8. Oncoproteomics: current trends and future perspectives.
Cho WC; Cheng CH
Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomics for drug toxicity.
Gao Y; Holland RD; Yu LR
Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance mechanisms in cancer cells: a proteomics perspective.
Verrills NM; Kavallaris M
Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in clinical oncoproteomics.
Jain KK
J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
[TBL] [Abstract][Full Text] [Related]
12. Current approaches to new drug development in cancer chemotherapy.
Zunino F; Capranico G; Pratesi G; Spinelli S
Farmaco; 1992 Sep; 47(9):1115-32. PubMed ID: 1300118
[TBL] [Abstract][Full Text] [Related]
13. The molecular make-up of a tumour: proteomics in cancer research.
Kolch W; Mischak H; Pitt AR
Clin Sci (Lond); 2005 May; 108(5):369-83. PubMed ID: 15831087
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in proteomics: implications for the study of cardiac hypertrophy and failure.
Faber MJ; Agnetti G; Bezstarosti K; Lankhuizen IM; Dalinghaus M; Guarnieri C; Caldarera CM; Helbing WA; Lamers JM
Cell Biochem Biophys; 2006; 44(1):11-29. PubMed ID: 16456231
[TBL] [Abstract][Full Text] [Related]
15. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
Hu S; Yen Y; Ann D; Wong DT
Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
[TBL] [Abstract][Full Text] [Related]
16. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
17. Integrative oncoproteomics strategies for anticancer drug discovery.
Liu R; Wang K; Yuan K; Wei Y; Huang C
Expert Rev Proteomics; 2010 Jun; 7(3):411-29. PubMed ID: 20536311
[TBL] [Abstract][Full Text] [Related]
18. Proteomic approaches for the identification of cell cycle-related drug targets.
Flory MR; Aebersold R
Prog Cell Cycle Res; 2003; 5():167-71. PubMed ID: 14593710
[TBL] [Abstract][Full Text] [Related]
19. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-DomÃnguez A; Comuzzie AG
Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
[TBL] [Abstract][Full Text] [Related]
20. Modeling of protein signaling networks in clinical proteomics.
Geho DH; Petricoin EF; Liotta LA; Araujo RP
Cold Spring Harb Symp Quant Biol; 2005; 70():517-24. PubMed ID: 16869790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
